Evaluation of potential anticonvulsant fluorinated N-benzamide enaminones as T-type Ca2+ channel blockers

Amaye, Isis J.; Jackson-Ayotunde, Patrice L.; Martin‐Caraballo, Miguel

doi:10.1016/j.bmc.2022.116766

Cited by 4 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several fluorinated N-benzamide enaminone analogues evaluated through significant inhibitory effect on T-type Ca 2+ channels: 1, 2, 3, 4, 5, and 6 (Figure 13). 90 3.5. Drugs Acting on Glutamate Receptor.…”

Section: Drugs Acting As Ca Channelmentioning

confidence: 99%

Anticonvulsant Classes and Possible Mechanism of Actions

Abd-Allah,

El-Mohsen Anwar,

Mohammed

et al. 2023

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Epilepsy is considered one of the most common neurological disorders worldwide; it needs long-term or life-long treatment. Despite the presence of several novel antiepileptic drugs, approximately 30% patients still suffer from drug-resistant epilepsy. Subsequently, searching for new anticonvulsants with lower toxicity and better efficacy is still in paramount demand. Using target-based studies in the discovery of novel antiepileptics is uncommon owing to the insufficient information on the molecular pathway of epilepsy and complex mode of action for most of known antiepileptic drugs. In this review, we investigated the properties of anticonvulsants, types of epileptic seizures, and mechanism of action for anticonvulsants.

show abstract

Section: Drugs Acting As Ca Channelmentioning

confidence: 99%

Anticonvulsant Classes and Possible Mechanism of Actions

Abd-Allah,

El-Mohsen Anwar,

Mohammed

et al. 2023

ACS Chem. Neurosci.

View full text Add to dashboard Cite

show abstract

“…[9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] Likewise, various research studies have shown that the Ca V 3.2 (T-type) voltage-gated calcium channel is also a promising therapeutic target for alleviating neuropathic pain. [24][25][26][28][29][30][31][32][33] Over the years, a small number of N-and T-type calcium channel blockers were evaluated in clinical trials for the treatment of neuropathic pain arising from various diseases. Unfortunately, the majority of drug candidates failed to meet the primary outcomes and were subsequently terminated.…”

Section: Introductionmentioning

confidence: 99%

“…9–27 Likewise, various research studies have shown that the Ca V 3.2 (T-type) voltage-gated calcium channel is also a promising therapeutic target for alleviating neuropathic pain. 24–26,28–33…”

Section: Introductionmentioning

confidence: 99%